Michigan hospitals are systematically exploiting a program for low-income patients, according to a new report.

Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug ...

The 340B Drug Pricing Program was meant to help low-income patients, writes Rick Dowlearn, but it’s being used by hospitals ...

While more than 2,900 U.S. hospitals hold tax-exempt status as nonprofits, critics argue they have undergone a “mission drift ...

Too many hospitals take advantage of 340B, intended to make medications affordable for low-income patients. A New York proposal would make things worse.

As the January 1 implementation date approaches, here is a quick guide to the controversial new rebate model for the 340B Drug Pricing Program and the legal battle to stop it.

A Colorado district court judge denied drug manufacturer AstraZeneca’s request for an injunction to block enforcement of a recent law barring drug manufacturers from imposing restrictions on covered ...

St. Mary's in Lewiston is a plaintiff in the suit, which targets a pilot program introduced by the Trump administration.

Healthcare policy changes may increase uncompensated care, stressing hospitals and the 340B program, crucial for subsidizing low-income patient care. The 340B rebate model, starting in 2026, could ...

Ten medications accounted for nearly one-third of 340B program-covered outpatient drugs in 2024, according to a Dec. 11 report.  The Health Resources and Services Administration, an HHS agency, ...

As we look ahead to 2026, the operational demands on 340B programs are increasing across every dimension. Between the implementation of the 340B ...